AIM Biotech
  • HOME
    • ABOUT US
    • CAREERS
    • NEWSROOM
  • TECHNOLOGY
    • TECHNOLOGY
    • APPLICATIONS
    • PUBLICATIONS
  • PRODUCTS
    • CHIPS
    • ACCESSORIES
    • RESEARCH SERVICES
  • PROTOCOLS
    • GENERAL PROTOCOLS
    • APPLICATION-SPECIFIC PROTOCOLS
    • VIDEOS
    • PROTOCOL SUBMISSION
  • SUPPORT
    • CONTACT US
    • FAQ
    • TIPS & TRICKS
    • BROCHURES
    • APPLICATION NOTES
    • FORUMS
  • STORE
    • DISTRIBUTORS

AIM Biotech founder Professor Roger Kamm is awarded the 2020 Shu Chien Achievement Award

6/1/2020

0 Comments

 
The Shu Chien Scientific Achievement Award is bestowed by the Biomedical Engineering Society's Cellular and Molecular Bioengineering SIG in recognition of Prof Kamm's "... his highly meritorious contributions to the field of cellular and molecular bioengineering, including groundbreaking scientific advances, the development of programs, and the mentoring and training of the next generation of scientists working in the field. ​ ... " 

Congratulations, Roger!

Picture
Photo by Tony Pulsone
0 Comments

Meet us at ASCB|EMBO 2019 in Washington DC

5/12/2019

0 Comments

 
Picture
The AIM team will be exhibiting at the  2019 ASCB | EMBO Meeting​ in Washington DC. The meeting will take place from December 7-11th, while the exhibition will be from 930am-4pm December 8-10th. 

See you at:
Booth 1002
Walter E. Washington Convention Center 
801 Mount Vernon Place, NW
Washington, DC 20001

​Please email us at info@aimbiotech.com if you would like to schedule a meeting.
0 Comments

Cell paper on "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma" features AIM Biotech chips for Ex Vivo Immune Checkpoint Assays to Validate Key Discoveries

1/11/2018

0 Comments

 
Picture
Picture
Sade-Feldman et al from the Massachusetts General Hospital Cancer Center, the Broad Institute, the Dana Farber Cancer Institute and others demonstrated in the Cell paper that: 
  • Single-cell RNA-seq reveals distinct CD45 + cells associated with clinical outcome 
  • The balance between two CD8 + T cell states is linked with tumor regression 
  • TCF7 +CD8 + T cell frequency in tumor tissue predicts response and better survival 
  • Dual blockade of CD39 with different checkpoint proteins enhances immunity
​Ex vivo culture of murine-derived organotypic tumor spheroids (MDOTS) in AIM Biotech chips is able to recapitulate the immune checkpoint response.  These assays were used to validate the authors' discoveries by co-culturing the MDOTS with defined CD8+ T cell populations (CD39+/TIM3+, CD39-/TIM3- or mixed 1:1) (see figure 5D).
0 Comments

Joint webinar with MilliporeSigma on"3D Organ-on-a-chip Applications using AIM Biotech chips"

18/10/2018

0 Comments

 
Picture
In vitro 3D cell culture models bridge the gap between conventional 2D cell culture and expensive in vivo animal models. Join our webinar, where we cover how to generate simple & complex 3D organ models for research, drug metabolism, and toxicity studies using the microfluidic 3D organ-on-a-chip from AIM Biotech. Register now at this link.
0 Comments

3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes

7/8/2018

0 Comments

 
A blood-brain barrier (BBB) model is achieved by co-culturing iPSC-derived endothelial cells, human astrocytes and pericytes in microfluidic chips featuring AIM's technology. The BBB model not only exhibits physiologically relevant structures but also has permeability that is comparable to the in vivo permeability measurement in rat brain.  From a recent publication in Biomaterials.
Picture
Update: A detailed protocol is available for the blood-brain barrier assay. Click on the button below:
BLOOD-BRAIN BARRIER
0 Comments

Nature Medicine paper on "Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses" employs AIM chips for in vitro immune checkpoint assays

30/7/2018

1 Comment

 
Picture
A Nature Medicine paper by researchers from the Dana-Farber Cancer Institute, NYU and others  features the discovery of a new genetic profile, SPARCS that predicts tumor immune response. The authors used AIM chips and human NSCLC biopsies to show that SPARCS_high profiles correspond with positive immune-checkpoint responses. 

1 Comment

Dana-Farber researchers culture patient-derived tumor spheroids in AIM chips to accurately predict their in vivo response to targeted therapies

14/4/2018

3 Comments

 
Picture
Dr Amir Aref of the Dana-Farber Cancer Institute will be sharing how short-term culture of organotypic patient tumor spheroids derived from patient xenografts in AIM chips predicts in vivo response of targeted therapies at AACR 2018 on Sunday 350pm 15th April (see the full abstract & details at this link)
3 Comments

Come & meet us at AACR 2018 in Chicago from 14-18th April 2018

14/4/2018

0 Comments

 
Picture
The AIM team will be exhibiting at the annual meeting of the American Association for Cancer Research in Chicago. The meeting will take place from April 14-18th, while the exhibition will be from April 15-18th. 
Come & see us at:
Booth 4132
McCormick Place North/South
Chicago, Illinois

Please email us at info@aimbiotech.com if you would like to schedule a meeting.
0 Comments

Meet us at ASCB|EMBO 2017 in Philadelphia from 3-5th December 2017

29/11/2017

0 Comments

 
Picture
The AIM team will be exhibiting at the  2017 ASCB | EMBO Meeting​ in Philadelphia. The meeting will take place from December 2-6th, while the exhibition will be from 930am-4pm December 3-5th. 

See you at:
Booth 340
Pennsylvania Convention Center,
1101 Arch St,
Philadelphia, PA 19107 USA.


​Please email us at info@aimbiotech.com if you would like to schedule a meeting.
0 Comments

Two Cancer Discovery papers feature a novel ex vivo immune checkpoint assay developed with AIM chips

9/11/2017

0 Comments

 
Picture
Picture
Researchers at the Dana-Farber Cancer Institute and MIT have developed a novel ex vivo assay (above) to profile the PD-1 blockade, making it possible to interrogate the tumor immune microenvironment, develop novel therapeutic combinations, and facilitate precision immuno-oncology efforts. The assay is detailed by Jenkins et al in “Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids“, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0833
 
The ex vivo organotypic tumor spheroid culture system was utilised by Deng et al to show that CDK4/6 inhibition augments the response to PD-1 blockade. The effect was validated in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. The results are detailed in “CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation”, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0915

Dana-Farber Cancer Institute news release (click here)

* Update 5th Sep 2018
Follow up publication:  *3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Aref AR,  Campisi M, Ivanova E, Portell A, Larios D, Piel BP... Jenkins RW. Lab on a Chip, 2018, DOI: 10.1039/C8LC00322J 
0 Comments
<<Previous

    Archives

    January 2020
    December 2019
    November 2018
    October 2018
    August 2018
    July 2018
    April 2018
    November 2017
    July 2017
    April 2017
    December 2016
    July 2016
    March 2016
    January 2016
    December 2015
    September 2015
    August 2015

    Categories

    All

    RSS Feed

Picture
About AIM Biotech
Contact Us
Newsroom
Subscribe to AIM Biotech's mailing list

This website and its content is copyright of AIM Biotech Pte. Ltd.
​© AIM Biotech Pte. Ltd. 2020. All rights reserved.